Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Gene mutations may provide clues for liver cancer survival
Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.
Gene mutations may provide clues for liver cancer survival
13 Oct 2021
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
While patients with haematological malignancies (HM) are able to mount a persistent antibody response against the spike (S) protein of the SARS-CoV-2 virus, early treatment with rituximab completely abolishes such response, a recent study has found. These findings could help inform coronavirus disease 2019 (COVID-19) vaccination policies for patients with HMs.
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
12 Oct 2021
Obesity may predispose individuals to early-onset colorectal adenocarcinoma
Individuals with obesity are at higher risk of developing early-onset colorectal adenocarcinoma compared with their normal-weight counterparts, as reported in a study.
Obesity may predispose individuals to early-onset colorectal adenocarcinoma
12 Oct 2021
MET amplification a predictor of response to crizotinib
A subanalysis of the ongoing phase II PROFILE 1001 study suggests that MET amplification may serve as one of the predictive biomarkers for response to crizotinib among patients with non-small-cell lung cancer (NSCLC).
MET amplification a predictor of response to crizotinib
12 Oct 2021
Real-world data suggest enzalutamide more suitable than abiraterone for post-docetaxel mCRPC
A real-world retrospective study reports significantly longer radiological progression-free survival (rPFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide vs abiraterone acetate after previous docetaxel therapy.
Real-world data suggest enzalutamide more suitable than abiraterone for post-docetaxel mCRPC
12 Oct 2021
Pseudopyloric metaplasia does not predict development of gastric cancer
Neither gastric cancer nor gastric dysplasia is seen in patients with corpus atrophic gastritis (CAG) characterized at baseline with corpus pseudopyloric metaplasia (PPM) without corpus intestinal metaplasia (IM) because such lesions are consistently associated with corpus IM, reports a study.
Pseudopyloric metaplasia does not predict development of gastric cancer
10 Oct 2021
Targeted therapy superior to chemotherapy, best supportive care at improving survival in NSCLC
Survival benefit in patients with de novo stage IV nonsmall-cell lung cancer (NSCLC) depends on the type of treatment received, with significantly better median overall survival (OS) seen with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements than with best supportive care, reports a study.
